U.S. FDA approves Mirati's lung cancer drug
12/12/2022 22:25
Dec 12 (Reuters) - The U.S. Food and Drug Administration on Monday approved Mirati Therapeutics Inc's MRTX.O lung cancer drug adagrasib, according to the health regulator's website. (Reporting by Raghav Mahobe in Bengaluru; Editing by Shounak Dasgupta) ((Raghav.Mahobe@thomsonreuters.com))
Recent news on Mirati Therapeutics
See all newsBrief: European Commission Approves KRAZATI As A Targeted Treatment For Non-Small Cell Lung Cancer
US FDA turns down Amgen lung cancer drug Lumakras for full approval (updated)
US FDA turns down Amgen lung cancer drug Lumakras for full approval
Brief: Mirati Stockholders Voted 'For' Proposal To Adopt Deal Between Co, Bristol-Myers Squibb
Mirati's lung cancer drug gets EU's regulatory backing (updated)